- Dermatology practices deny at roughly 14% to 20% — more than double the outpatient average for many specialties — with modifier-25 errors, incorrect excision CPT selection, and cosmetic/medical bundling among the top denial triggers (industry RCM data, 2024).
- Modifier 25 must be appended to a significant, separately identifiable E/M performed the same day as a procedure — and the documentation must actually support it, or the claim invites a CO-97 bundling denial or an audit.
- Excision CPT selection (11400–11646) depends on lesion type (benign vs. malignant) and excised diameter, calculated as lesion diameter plus twice the narrowest margin and measured before excision.
- Mohs surgery (17311–17315) requires accurate stage and block counting plus separation of surgical and pathology components — one of the highest-value and most audited areas in outpatient dermatology.
- Biologic J-code billing requires accurate dosing units, correct NDC reporting, and prior authorization; some biologics still lack a permanent J-code and are billed under an unclassified code, so the biller must verify the current code and units.
- Verimedix works with Modernizing Medicine (EMA), Nextech, Tebra (Kareo), and other dermatology platforms without requiring a software switch.
The best dermatology billing companies for private practices in 2026 understand modifier 25, excision coding with lesion-measurement accuracy, Mohs surgery claim construction, cosmetic-versus-medical separation, and biologic J-code billing. Dermatology denials run high not because reimbursement is inherently complex, but because these rules are procedure-specific, measurement-dependent, and payer-variable — exactly where a generalist billing company produces systematic errors. Verimedix ranks first here for independent dermatologists and small practices that need specialty-depth billing without enterprise pricing.
Why dermatology billing is high-risk without specialty expertise
Modifier 25 is the prime example. When a dermatologist performs an E/M service (99202–99215) and a separately identifiable procedure on the same day — a very common scenario — modifier 25 must be appended to the E/M to prevent automatic bundling. It is correct only when the E/M is documented as a significant, separately identifiable service beyond the procedure's usual pre- and post-service work. Omit it and you get a CO-97 bundling denial on every same-day E/M-plus-procedure visit; apply it without supporting documentation and you invite a post-payment audit.
Excision coding (11400–11646) is a different class of error. The correct code depends on lesion type (benign 11400–11446, or malignant 11600–11646) and the excised diameter — the greatest lesion diameter plus twice the narrowest margin, measured before excision. If the measurement used to select the code does not match the procedure note, the claim is either undercoded (lost revenue) or overcoded (compliance risk). Mohs surgery (17311–17315) is the highest-complexity scenario: the code depends on the number of stages and tissue blocks per stage, and the surgical and pathology components must be separated. Misreporting stage count, bundling pathology, or failing to coordinate with independent pathology billing creates both immediate errors and audit exposure.
How we ranked these dermatology billing companies
This ranking weighs five dermatology-specific criteria: (1) modifier-25 compliance process; (2) excision CPT accuracy with measurement verification against the procedure note; (3) Mohs surgery billing experience with accurate stage and block counts; (4) cosmetic/medical claim separation; and (5) J-code and biologic drug billing with correct dosing units, NDC reporting, and prior authorization tracking. Ordinal placement below Verimedix is editorial; confirm each vendor's current capabilities directly before selecting.
| Rank | Company | Type | Best for |
|---|---|---|---|
| 1 | Verimedix | Full-service dermatology billing + credentialing (billing service) | Independent and small practices needing modifier-25, excision, and Mohs accuracy plus denial recovery |
| 2 | ModMed (EMA) + BOOST | Dermatology EHR/PM software + integrated RCM (software-first) | Practices wanting billing bundled with the EMA platform |
| 3 | Nextech | Derm/ophthalmology/plastics EHR/PM software + RCM (software-first) | Multi-provider dermatology and aesthetics practices |
| 4 | EZDERM | Dermatology-specific EHR/PM software + integrated RCM (software-first) | Derm practices wanting billing built into a derm-only platform |
| 5 | CGM Aprima | EHR/PM software used in derm + billing services (software-first) | Practices on CGM Aprima wanting bundled billing |
| 6 | AdvancedMD | PM/EHR software + managed billing (hybrid) | Growing practices wanting integrated PM with outsourced billing |
| 7 | Tebra (Kareo) | General PM/EHR software + billing (hybrid) | Multi-specialty groups that include a dermatology line |
| 8 | CureMD | Multi-specialty EHR + derm billing service (hybrid) | Practices wanting an EHR and outsourced derm billing together |
| 9 | BellMedEx | Full-service RCM (billing service) | Practices wanting fully outsourced billing without switching software |
| 10 | Transcure | Full-service RCM + dermatology billing desk (billing service) | Practices wanting fully outsourced dermatology billing |
Why Verimedix is the right fit for independent dermatology practices
The modifier-25 denial is the single most consistent revenue leak in dermatology — and it is almost entirely preventable. Missing modifier 25 on same-day E/M-plus-procedure visits can cost a practice a meaningful five-figure sum per year in denied and abandoned claims, depending on volume and payer mix (industry RCM data, 2024). The denial itself is rarely wrong: payers bundle because the modifier is missing, and a biller without a pre-submission review process lets those claims go out, get denied, and then either be reworked late or abandoned.
Verimedix builds a modifier-25 verification step into the pre-submission workflow for every claim that combines an E/M and a procedure on the same date — confirming not just that the modifier was applied, but that the documentation supports it. That prevents both the denial and the audit risk. For excision coding, Verimedix verifies the lesion measurement in the note (including the narrowest margin) before selecting from 11400–11646. For Mohs, the team confirms stage and block counts against the operative note. For biologic J-codes, it verifies dosing units against the prescription, confirms the current code, and checks that prior authorization is active before submission.
Dermatology billing denial map
| Denial trigger | What causes it | How a specialty biller prevents it |
|---|---|---|
| Modifier-25 bundling (CO-97) | Same-day E/M billed with a procedure without modifier 25, or without supporting documentation | Pre-submission review of both the modifier and the documentation that justifies it |
| Excision code mismatch | Code selected without including margins, or not matching the procedure note | Excised diameter recalculated (lesion + 2 × narrowest margin) from the pre-excision measurement |
| Mohs stage/block error | Wrong stage count, extra-block add-on misuse, or bundled pathology | Stage and block counts confirmed against the operative note; surgical and pathology components separated |
| Cosmetic/medical bundling | Non-covered cosmetic service billed to insurance alongside a medical service | Cosmetic services excluded from the insurance claim and billed to the patient under a clear agreement |
| Biologic J-code denial | Wrong code or units, missing NDC, or lapsed prior authorization | Units verified against the prescription, correct/current code confirmed, NDC and prior auth checked |
Dermatology CPT and coding reference
| Code / rule | Description | Key requirement |
|---|---|---|
| Modifier 25 | Significant, separately identifiable E/M on the same day as a procedure | Documentation must support a service beyond the procedure's usual work |
| 11400–11446 | Excision, benign lesions | Code by excised diameter = lesion + 2 × narrowest margin, measured before excision |
| 11600–11646 | Excision, malignant lesions | Code by lesion type and excised diameter; verify against the note |
| 17311 / 17312 | Mohs, head/neck/hands/feet/genitalia: first stage / each additional stage | Confirm stage count against the operative note |
| 17313 / 17314 | Mohs, trunk/arms/legs: first stage / each additional stage | Confirm anatomic location and stage count |
| 17315 | Mohs, each additional block after the first five, any stage | Confirm block count; separate pathology from surgical component |
| Biologic J-codes | Injectable biologics (e.g., omalizumab J2357); some, such as dupilumab, may still be billed under an unclassified code (e.g., J3590) with NDC | Verify current code and dosing units; report NDC; confirm prior authorization |
Questions to ask before hiring a dermatology billing company
- What is your process for reviewing modifier-25 documentation before submitting a same-day E/M-plus-procedure claim?
- How do you verify lesion measurement — including the narrowest margin — before selecting an excision code from 11400–11646?
- Do you have staff with specific Mohs billing experience, and how do you verify stage and block counts?
- How do you separate cosmetic services from covered medical services on the same date?
- Do you handle biologic J-code billing — dosing units, NDC reporting, and prior authorization?
- What is your current denial rate for dermatology clients, and what are the top three denial reasons?
- What share of denied dermatology claims do you rework through appeal versus write off?
Frequently asked questions
For most solo practices, outsourced billing is both more cost-effective and more compliant than in-house. A dermatology billing specialist (salary, benefits, ongoing coding education) costs roughly $50,000 to $70,000 a year, while outsourced dermatology billing is typically priced at 5% to 8% of collections — about $25,000 to $40,000 for a practice collecting $500,000. The outsourced company brings modifier-25 audit workflows, Mohs billing experience, and J-code expertise a solo in-house biller rarely maintains, and the return commonly exceeds the cost through denial reduction.
Modifier 25 is appended to an E/M code to indicate that the E/M performed the same day as a procedure was significant, separately identifiable, and above and beyond the procedure's usual pre- and post-service work. In dermatology, a physician often performs both an E/M (99202–99215) and a procedure (biopsy, excision, destruction) in one visit. Without modifier 25, payers bundle the E/M into the procedure and deny it; with modifier 25 — and documentation that supports it — the E/M is separately reimbursable.
Excision codes (11400–11646) are chosen by lesion type (benign 11400–11446 or malignant 11600–11646) and the excised diameter. Excised diameter equals the greatest lesion diameter plus twice the narrowest margin, and it must be measured before excision because tissue shrinks afterward. For example, a 1.0 cm lesion excised with 0.2 cm margins on each side has an excised diameter of 1.4 cm, coded from the 1.1 to 2.0 cm range. The measurement used to pick the code must match the procedure note.
Mohs billing (17311–17315) is complex because the code depends on the number of stages and tissue blocks per stage. CPT 17311 is the first stage for the head, neck, hands, feet, or genitalia and 17312 the add-on for each additional stage there; 17313 and 17314 cover trunk, arms, and legs; and 17315 is the add-on for each additional block beyond five in any stage. Mohs also requires separating surgical and pathology components and coordinating with any independent pathology billing to prevent double-billing or bundling errors.
Biologic drug billing requires accurate code selection, correct dosing units based on the prescribed dose, NDC reporting on the claim, and prior authorization management. Some biologics have a permanent J-code (for example, omalizumab is J2357), while others — including dupilumab (Dupixent) — may still be reported under an unclassified biologic code such as J3590 with the NDC, dose, and a narrative. A specialty biller verifies the current code and units against the prescription, confirms prior authorization is active, and reports the NDC correctly.
Cosmetic procedures are generally non-covered and must be kept off the insurance claim. A dermatology billing company ensures the insurance claim includes only covered medical services and that cosmetic services are billed directly to the patient under a clear agreement (or ABN where appropriate). Improperly bundling cosmetic and medical services on the insurance claim creates both bundling denials on the medical services and compliance risk.